Follow NCRAS on Twitter!
Join the NCRASmailing list!
Accessing cancer registration and other datasets.
Oncology training for NHS and Public Health non-clinical staff.
2015 Cancer incidence and mortality numbers and rates published by ONS and PHE.
NCRAS is part of Public Health England (PHE), which exists to protect and improve the nation's health and wellbeing, as well as reduce health inequalities. PHE is an executive agency of the Department of Health, and a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.
The use MY data website has information on the benefits of using patient data.
The National Cancer Registration and Analysis Service
In 2016 the National Cancer Intelligence Network (NCIN) and National Disease Regsitration (NDR) merged to form the National Cancer Registration and Analysis Service (NCRAS). NCRAS works to drive improvements in standards of cancer care and clinical outcomes by improving and using the information collected about cancer patients for analysis, publication and research.
30 years of cancer intelligence - a look back on the history.
Find out more about NCRAS.
Achieving World Class Cancer Outcomes - A strategy for England - Executive summary and Report
Data drawn from Routes to Diagnosis, cancer staging and CancerData. Please see sources for more information.
Most recent publications
The following is a list of the most recent publications produced by NCRAS
Incidence, survival, patient experience and quality of life metrics providing data to help achieve the ambitions set out by the Independent Cancer Taskforce.
This blog discusses incidence and survival data for childhood cancers using data from a recent NCRAS report.
NCRAS and ONS published survival statistics for cancer patients diagnosed between 2012 and 2014, highlighting variation in survival by stage.
This paper, published with several NCRAS staff, uses Systemic Anti-Cancer Therapy (SACT) data to examine 30-day mortality and establish benchmarks for breast and lung cancer after chemotherapy treatment.